Andrx
This article was originally published in The Tan Sheet
Executive Summary
Company's extended-release pseudoephedrine technology licensed by Bayer Consumer Care for its Aleve Cold & Sinus product, which launched in August and will be backed by a $19 mil. ad spend beginning in mid-September (1"The Tan Sheet" June 5, p. 6). While the Fort Lauderdale, Fla.-based firm has an agreement with Bayer to work on another undisclosed OTC, Andrx said the project is on the back burner as both companies reevaluate how to focus their energies
You may also be interested in...
Aleve Cold & Sinus Bolstered By $19 Mil. Ad Spend
Bayer Consumer Care's Aleve Cold & Sinus - "the only brand that can provide all day relief of pain and nasal congestion with just one pill" - will arrive on food, drug and mass shelves nationwide in August. The launch comes nearly nine months after FDA approval.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands